The European Society for Paediatric Oncology (SIOPE) welcomes the European Competitiveness Fund (ECF) regulation proposal and its scope of activities. We believe ensuring a focus on childhood cancer within these areas can reinforce the political resolve across Europe to restore its competitive edge and ensure prosperity.
SIO
SIOPE
NGO · Belgium · EU Transparency Register 122803916413-09
9
positions filed
in the 665 files tracked
7
legislative files
of 665 tracked
6
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #176 by legislative files engaged, a count of participation, not a measure of influence.
3.3
declared lobbying FTE
self-declared
–
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2015
in the register since
Declares membership of
- https://siope.eu/activities/partnerships/
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Non-governmental organisations
- Registered as
- European Society for Paediatric Oncology (SIOP Europe / SIOPE)
- Head office
- Brussels, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track SIOPE in PolicySpeak: request access →
Work at SIOPE? so we know who speaks for it.
Their record over time
SIOPE filed 9 positions between 6 Jan 2021 and 12 Nov 2025, across 7 of the 665 legislative files tracked here, attaching a full position paper 6 times.
2021 · 3 filed2023 · 1 filed2024 · 1 filed2025 · 4 filed
What they argued
The European Society for Paediatric Oncology (SIOPE) welcomes the Horizon Europe (20282034) proposal and asks the Commission to make childhood cancer a clear, visible priority across Pillar IIIV by funding the research infrastructure and cross-border collaboration that delivers results.
1. Unmet Medical Needs (UMN) and High Unmet Medical Needs (high UMN): We argue that investment in novel medicines overall reduces the financial burden of governments. New drugs that bear lower toxicity levels would reduce long term side effects of paediatric cancer patients and enable them to be productive members of society later in life.
SIOPE welcome evaluation and revision of General Pharmaceutical Legislation hoping that it can deliver urgently needed improvements for over 6000 youngest citizens dying of cancer each year in Europe by addressing: 1.Revise Legislation to Unlock Innovation Concluded by Paediatric and Orphan Regulations (OPR) evaluation “neither regulation has proven effective in boosting development of innovative medicines for…
SIOPE (the European Society for Paediatric Oncology) welcomes the opportunity to contribute to the EU Biotech Act consultation on behalf of the childhood cancer community. Cancer remains the leading cause of disease-related death in children and adolescents in Europe, yet innovation continues to bypass the specific needs of this population.
SIOPE welcomes the European Innovation Act as a potentially useful instrument to shift gears in paediatric oncology innovation, and our aim is clear: to see more start-ups and biotech companies sustaining and scaling up innovation for children with cancer, namely start-ups focused on specific paediatric oncology drug development, including ATMPs.
SIOP Europe welcomes the European Health Data Space Roadmap with its focus on eradicating inequalities, facilitating research, and empowering patients. The roadmap objective 1: ‘Legal and governance framework to cover the access to and exchange of health data’ is particularly relevant for addressing the challenges and opportunities in the paediatric sector.
SIOPE and CCI-E welcome the proposed revision of EU regulations on medicines for children and rare diseases. All paediatric cancers individually are rare, but jointly are the leading cause of death by disease in children above one year of age in Europe. Most survivors experience long-term side-effects due to older medicines.
The European Society for Paediatric Oncology (SIOP Europe, or SIOPE) is the only pan-European organisation representing all professionals working in the field of childhood cancers. The rarity and specificity of childhood cancers combined with their high overall burden in Europe require funding opportunities specifically addressing this disease area.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put SIOPE next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 194.
Is this your organization?
Everything on this page comes from SIOPE’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.